Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges

European Child and Adolescent Psychiatry

Volumn 23, Issue 12, 2014, Pages 1149-1160

  Glennon, Jeffrey ^a   Purper Ouakil, Diane ^b,c   Bakker, Mireille ^a   Zuddas, Alessandro ^d   Hoekstra, Pieter ^e,u   Schulze, Ulrike ^j   Castro Fornieles, Josefina ^k   Santosh, Paramala J ^f,g   Arango, Celso ^h   Kölch, Michael ^j   Coghill, David ⁱ   Flamarique, Itziar ^k   Penzol, Maria J ^h   Wan, Mandy ^l   Murray, Macey ^m   Wong, Ian C K ⁿ   Danckaerts, Marina ^o   Bonnot, Olivier ^p   Falissard, Bruno ^q   Masi, Gabriele ^r   Fegert, Jörg M ^j   Vicari, Stefano ^s   Carucci, Sara ^d   Dittmann, Ralf W ^t   Buitelaar, Jan K ^a   more..

^a RADBOUD UNIVERSITY   (Netherlands)

^b HÔPITAL SAINT ELOI   (France)

^c CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^d DEPARTMENT OF RADIOLOGY   (Italy)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

ⁱ UNIVERSITY OF DUNDEE   (United Kingdom)

^j UNIVERSITY OF ULM   (Germany)

^k UNIVERSITY OF BARCELONA   (Spain)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF LONDON   (United Kingdom)

ⁿ UNIVERSITY OF HONG KONG   (Hong Kong)

^o KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^p Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent de Nantes   (France)

^q Universite Paris Sud   (France)

^r DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

^s BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^t CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^u UNIVERSITY OF GRONINGEN   (Netherlands)

more..

Author keywords

Conduct disorder; Pharmacovigilance; Psychopharmacology; Randomised clinical trials; Risperidone

Indexed keywords

PROLACTIN; RISPERIDONE; NEUROLEPTIC AGENT;

ARTICLE; BODY WEIGHT DISORDER; CHILD PSYCHIATRY; CONDUCT DISORDER; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSKINESIA; EMOTIONAL DISORDER; EXPLORATORY RESEARCH; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; MAINTENANCE THERAPY; MEDICAL EDUCATION; MEDICAL ETHICS; METABOLIC DISORDER; MULTICENTER STUDY (TOPIC); OBESITY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SEXUAL DYSFUNCTION; SHORT COURSE THERAPY; SOMNOLENCE; TREMOR; ADOLESCENT; CHILD; CLINICAL TRIAL (TOPIC); EUROPE; PEDIATRICS; TREATMENT OUTCOME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; CONDUCT DISORDER; EUROPE; HUMANS; PEDIATRICS; PHARMACOVIGILANCE; PSYCHOPHARMACOLOGY; RISPERIDONE; TREATMENT OUTCOME;

EID: 84912138708     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-013-0498-3     Document Type: Article

References (54)

1. Patten SB, Waheed W, Bresee L (2012) A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents. Can J Psychiatry 57(12):717–721
2. Arango C (2011) Child and adolescent neuropsychopharmacology: now or never. Eur Neuropsychopharmacol 21(8):563–564
3. Noguera A et al (2013) Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability. J Clin Psychopharmacol 33(4):463–471
4. Matone M et al (2012) The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children. Health Serv Res 47(5):1836–1860
5. Olfson M et al (2012) National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 69(12):1247–1256
6. Rani F et al (2008) Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121(5):1002–1009
7. Kalverdijk LJ et al (2008) Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 59(5):554–560
8. Fraguas D et al (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21(8):621–645
9. Fraguas D et al (2008) Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 69(7):1166–1175
10. Arango C (2013) To treat or not to treat? and How to treat?. Two questions whose answers are far removed from evidence informed practice in child psychiatry, Eur Child Adolesc Psychiatry
11. Rapoport JL (2013) Pediatric psychopharmacology: too much or too little? World Psychiatry 12(2):118–123
12. Costello EJ et al (2003) Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 60(8):837–844
13. Shivram R et al (2009) Service utilization by children with conduct disorders: findings from the 2004 Great Britain child mental health survey. Eur Child Adolesc Psychiatry 18(9):555–563
14. Rowe R et al (2010) Developmental pathways in oppositional defiant disorder and conduct disorder. J Abnorm Psychol 119(4):726–738
15. Morcillo C et al (2012) Conduct disorder and adult psychiatric diagnoses: associations and gender differences in the US adult population. J Psychiatr Res 46(3):323–330
16. Bywater T et al (2009) Long-term effectiveness of a parenting intervention for children at risk of developing conduct disorder. Br J Psychiatry 195(4):318–324
17. Henggeler SW, Sheidow AJ (2012) Empirically supported family-based treatments for conduct disorder and delinquency in adolescents. J Marital Fam Ther 38(1):30–58
18. Lochman JE et al (2011) Cognitive-behavioral therapy for externalizing disorders in children and adolescents. Child Adolesc Psychiatr Clin N Am 20(2):305–318
19. Nevels RM et al (2010) Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol 18(2):184–201
20. Loy JH et al (2012) Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev 9:CD008559
21. Pappadopulos E et al (2006) Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry 15(1):27–39
22. Croonenberghs J et al (2005) Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44(1):64–72
23. Reyes M et al (2006) Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 16(3):260–272
24. Correll CU (2008) Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69(Suppl 4):26–36
25. Pringsheim T et al (2011) Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health 16(9):581–589
26. Fleischhaker C et al (2008) Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 115(11):1599–1608
27. Correll CU et al (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302(16):1765–1773
28. Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 21(8):600–620
29. Findling RL et al (2003) Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64(11):1362–1369
30. Laita P et al (2007) Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 17(4):487–502
31. Roke Y et al (2012) Risk of hyperprolactinemia and sexual side effects in males 10–20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol 22(6):432–439
32. Correll CU (2008) Effect of hyperprolactinemia during development in children and adolescents. J Clin Psychiatry 69(8):e24
33. Kaufman J et al (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36(7):980–988
34. Aman M et al (2008) The Nisonger Child Behavior Rating Form: typical IQ version. Int Clin Psychopharmacol 23(4):232–242
35. Guy W (1976) ECDEU Assessment Manual for Psychoparmacology. US Department of Health, Education and Welfare, Washington, DC (reprinted 1991)
36. Coccaro EF et al (1991) Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci 3(2):S44–S51
37. Yudofsky SC et al (1986) The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 143(1):35–39
38. Shaffer D et al (1983) A children’s global assessment scale (CGAS). Arch Gen Psychiatry 40(11):1228–1231
39. Riley AW et al (2004) The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care 42(3):210–220
40. DuPaul GJ (1998) ADHD rating-scale-IV: checklists, norms and clinical interpretation. Guilford Press, New York
41. De Sonneville LMJ (1999) Amsterdam neuropsychological task: a computer-aided assessment program. In: Brinker BPLM et al (eds) Cognitve ergonomics, clincial assessment and computer-assisted learning: computers in psychology. Swets & Zeitlinger, Liss, Netherlands
42. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676
43. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19
44. Posner K et al (2011) The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168(12):1266–1277
45. Calarge CA et al (2009) Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 19(2):101–109
46. Calarge CA et al (2012) Rate of weight gain and cardiometabolic abnormalities in children and adolescents. J Pediatr 161(6):1010–1015
47. Vitiello B et al (2009) Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19(9):629–635
48. Hoekstra PJ et al (2010) Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. J Child Adolesc Psychopharmacol 20(6):473–477
49. Calarge CA et al (2009) Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 19(5):373–382
50. Frick PJ, White SF (2008) Research review: the importance of callous-unemotional traits for developmental models of aggressive and antisocial behavior. J Child Psychol Psychiatry 49(4):359–375
51. Connor DF et al (2004) Proactive and reactive aggression in referred children and adolescents. Am J Orthopsychiatry 74(2):129–136
52. Lahey BB et al (2002) Adolescent outcomes of childhood conduct disorder among clinic-referred boys: predictors of improvement. J Abnorm Child Psychol 30(4):333–348
53. Burke JD, Loeber R, Birmaher B (2002) Oppositional defiant disorder and conduct disorder: a review of the past 10 years, part II. J Am Acad Child Adolesc Psychiatry 41(11):1275–1293
54. Lahey BB et al (1994) DSM-IV field trials for oppositional defiant disorder and conduct disorder in children and adolescents. Am J Psychiatry 151(8):1163–1171